Charles Baker-glenn

Title: Charles Baker-Glenn: Innovator in Pharmaceutical Chemistry

Introduction

Charles Baker-Glenn is a notable inventor based in Parma, Italy. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific receptors in the human body. His work has the potential to impact the treatment of various respiratory diseases.

Latest Patents

One of his key patents is titled "Amino quinazoline derivatives as P2X3 inhibitors." This invention relates to compounds that inhibit the P2X purinoceptor 3, specifically focusing on amino quinazoline derivatives. The patent outlines methods for preparing these compounds, pharmaceutical compositions that contain them, and their therapeutic uses. The compounds may be beneficial in treating disorders associated with P2X receptor mechanisms, including respiratory diseases such as cough, asthma, idiopathic pulmonary fibrosis (IPF), and chronic obstructive pulmonary disease (COPD). Charles Baker-Glenn holds 1 patent in this area.

Career Highlights

Charles Baker-Glenn is associated with Chiesi Farmaceutici S.p.a., a company known for its commitment to developing innovative pharmaceutical solutions. His work at Chiesi has allowed him to focus on creating effective treatments for respiratory conditions, contributing to the company's mission of improving patient health.

Collaborations

Throughout his career, Charles has collaborated with esteemed colleagues, including Claudio Fiorelli and Paolo Bruno. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic compounds.

Conclusion

Charles Baker-Glenn is a prominent figure in the field of pharmaceutical innovation, with a focus on developing compounds that address critical health issues. His contributions, particularly in the area of P2X3 inhibitors, highlight the importance of targeted therapies in modern medicine.